Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLEM: Avelumab in Stage III dMMR/POLE Mutant Colon Cancer
NCT03827044Phase 3Terminated
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Aug 2018
- Primary completion
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab in colon cancer (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Disease Free Survival at 3 years. Started Aug 2018; status: terminated.
02
Drugs
avelumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT03827044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827044.